Skip to main content
SpringerLink
Log in

Neoadjuvant Docetaxel in Locally Advanced Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Neoadjuvant chemotherapy produces substantial increases in clinical response rates and rates of breast conserving therapy. Pathologic response rate, though generally low, is an important outcome as it is presumably associated with eradication of micrometastatic disease and may likely result in improved outcomes. Anthracyclines have long been considered the most efficacious chemotherapy agents for neoadjuvant therapy of early breast cancer. Unfortunately, not all patients respond to neoadjuvant anthracycline-based chemotherapy. In an effort to improve primary tumor response, docetaxel, an active agent in breast cancer, has been evaluated in the neoadjuvant setting. Several randomized trials, including the NSABP B-27, GEPAR-duo, and the Aberdeen trial, evaluating docetaxel in sequence with a doxorubicin-based neoadjuvant regimen have been reported, with encouraging findings. We designed the Aberdeen trial with two primary aims: (1) to evaluate primary docetaxel in patients that initially fail a neoadjuvant anthracycline-based polychemotherapy regimen, and (2) to compare a docetaxel-based neoadjuvant regimen with a standard anthracycline-based regimen in patients who do respond to the first four cycles of the anthracycline-based regimen. Eligible patients (n = 162) had previously untreated large (≥3 cm) or locally advanced (T3, T4, T x N2) breast cancer. All received four cycles of CVAP, after which clinical response was assessed. Responding patients were then randomized to four additional cycles of CVAP or to docetaxel 100 mg/m2 every 3 weeks for four cycles. Patients failing to respond to CVAP received the docetaxel regimen. After the first four cycles of CVAP, the overall response rate (ORR) was 67%. Ultimately, responses were higher in the group randomized to docetaxel compared with those continuing CVAP (cCR: 94% v.s. 66%; p = 0.001; pCR 34% v.s. 16%; p = 0.04). The addition of docetaxel improved overall survival and disease-free survival for patients responding to four cycles of CVAP as compared with those receiving eight cycles of CVAP. Relative dose intensity was higher and the incidence of severe leukopenia was lower in the group randomized to docetaxel. These data and data from the NSABP B-27 and GEPAR-duo trials strongly support a combined anthracycline/docetaxel regimen in the neoadjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998

    Google Scholar 

  2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer-Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19: 3817-3827, 2001

    Google Scholar 

  3. Smith IC, Heys DS, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Karkar TK, Eggleton SP, Ogston KN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002

    Google Scholar 

  4. Ravdin PM: Anthracycline resistance in breast cancer: clinical applications of current knowledge. Eur J Cancer 31A(Suppl 7): S11-S14, 1995

    Google Scholar 

  5. Kaye SB: Multidrug resistance in breast cancer: is the jury in yet? J Natl Cancer Inst 89: 902-902, 1997

    Google Scholar 

  6. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917-931, 1997

    Google Scholar 

  7. Neilsen D, Maare C, Skovsgaard T: Cellular resistance to anthracyclines. Gen Pharmacol 27: 251-255, 1996

    Google Scholar 

  8. Chan S, Friedrichs K, Noel D et al., for the 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999

    Google Scholar 

  9. Nabholtz JM, Senn HJ, Bezwoda WR et al.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413-1424, 1999

    Google Scholar 

  10. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J: Docetaxel compared with sequential methotrexate and 5-florouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201, 1999

    Google Scholar 

  11. Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 11(Suppl 8): 15-18, 1997

    Google Scholar 

  12. Amat S, Body G, Bougnoux P, Charrier S, Chevrier R, Chollet P, Cure H, Dauplat H, Praagh I: Induction chemotherapy in operable breast cancer: high pathological response rate induced by docetaxel. Proc Am Soc Clin Oncol 18: 79a, 1999 (abstract 297)

    Google Scholar 

  13. Tubiana-Hulin M, Dieras V, Fumoleau P, Combe M, Misset J, Vannetzel J, Bachelot T, Boccara C, Ganem G: Phase II trial combining docetaxel (D) doxorubicine (DOX) as neoadjuvant treatment in patients (Pts) with operable breast carcinoma (BC). Proc Am Soc Clin Oncol 19: 127a, 2000 (abstract 495)

    Google Scholar 

  14. Lara F, De la Garza J, Ramirez T, Perez V, Salas E, Alvarado A, Poitevin A, Fuentes A, Robles C, Zinser J: High pathological complete response (PCR) after neoadjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Proc Am Soc Clin Oncol 19: 126a, 2000 (abstract 492)

    Google Scholar 

  15. Limentani SA, Erban JK, Sprague KA, Packman CH, O'Leary ML, Parma CC: Phase II study of doxorubicin and docetaxel as neoadjuvant therapy for women with stage IIB or III breast cancer. Proc Am Soc Clin Oncol 19: 131a, 2000 (abstract 511)

    Google Scholar 

  16. Valero V, Esteva FJ, Rosales MF, Esparza-Guerra LT, Sahin AA, Strom EA, RossMI, Booser DJ, Ibrahim NK, Cristofanilli M, Hunt KK, Hortobagyi GN: Phase II trial of primary chemotherapy with docetaxel and doxorubicin in locally advanced breast cancer: clinical and pathological results. Proc Am Soc Clin Oncol 19: 132a, 2000 (abstract 519)

    Google Scholar 

  17. Hurley J, Doliny P, Silva O, Gomez-Fernandez C, Reis I, Velez P, Castillo M, Bateman D, Franco S, Gautam U: Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 21: 50a, 2002 (abstract 196, updated based on poster)

    Google Scholar 

  18. de Matteis A, Nuzzo F, D'Aiuto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E, Perrone F: Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a singlecenter, phase II study. Cancer 94: 895-901, 2002

    Google Scholar 

  19. Alkhatib F, Grohn P, Trad D, Attia N, Zaher A: Docetaxel and epirubicin as neoadjuvant chemotherapy in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 21: 64b, 2002 (abstract 2068)

    Google Scholar 

  20. Minton SE, Muro-Cacho C, Diaz N, Bowman T, Cox C, Dupont E, Shons K, Fields K, Dalton W, Sullivan D, Richard J: A phase II neoadjuvant trial of sequential doxorubicin and docetaxel for the treatment of stage III breast cancer measuring signal transducers and activators of transcription (STAT) activation as a predictor of response to therapy. Proc Am Soc Clin Oncol 21: 32a, 2002 (abstract 125)

    Google Scholar 

  21. Teston L, Cooper B, Silverman P, Overmoyer B, Schnur G, Shenk R, Samuels J, Pham H, Moss T: Dose-dense chemotherapy with sequential doxorubicin (D) and docetaxel (Dt) for initial treatment of operable and inoperable stage II-IIIb breast cancer. Proc Am Soc Clin Oncol 19: 134a, 2000 (abstract 524)

    Google Scholar 

  22. Wynendaele W, Paridaens R, Van den Bogaert W, Christiaens MR, van Oosterom AT: Neoadjuvant chemotherapy with sequential doxorubicin (DOX) and docetaxel (DOC) in locally advanced breast cancer (LABC): a pilot study. Proc Am Soc Clin Oncol 18: 106a, 1999 (abstract 389)

    Google Scholar 

  23. von Minckwitz G, Raab G, Schuette M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe W, Jackisch C, duBois A, Caputo A, Kaufmann M: Dose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0)-primary endpoint analysis of the GEPARDUOStudy. Proc Am Soc Clin Oncol 21: 43a, 2002 (abstract 168)

    Google Scholar 

  24. NSABP: The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27. Breast Cancer Res Treat 69: 210, 2001

    Google Scholar 

  25. Hutcheon AW, Heys SD, Miller ID, Payne S, Smith IC, Ogston KN, Eremin OF, Sakrak TK: Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomized controlled trial. Breast Cancer Res Treat 69: 298, 2001

    Google Scholar 

  26. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901-906, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Aberdeen and Grampian University Hospitals, Aberdeen, Scotland

    Andrew W. Hutcheon, Steven D. Heys & Tarun K. Sarkar

Authors
  1. Andrew W. Hutcheon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven D. Heys
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tarun K. Sarkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hutcheon, A.W., Heys, S.D. & Sarkar, T.K. Neoadjuvant Docetaxel in Locally Advanced Breast Cancer. Breast Cancer Res Treat 79 (Suppl 1), 19–24 (2003). https://doi.org/10.1023/A:1024333725148

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024333725148

Search

Navigation